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Figure: Expression of IGF1R (A), IRS1 (B), IGFBP1 (C), IGFBP3 (D), IGFBP5 (E)
and IGFBP6 (F) in preserved and degenerated areas of human OA cartilage.
Results of qPCR analysis coupled with laser capture microdissection.
Pres, preserved area; Deg, degenerated area. **p< 0.01 against preserved
areas.
Results: Using microarray data, expression of possible anabolic factors
for chondrocytes (growth factors and anabolic cytokines) and related
molecules (receptors, antagonists and molecules related to signal
transduction) was compared between the degenerated areas and
preserved areas. This comparison revealed that the expression of IGF1R
and IRS1 could be reduced, and the expression of IGF-BP1, 3, 5 and 6
could be increased in degenerated areas. These ﬁndings were conﬁrmed
by qPCR analysis combined with LCM (Figure). The reduction in IGF1R
and IRS1 and the increase in IGF-BP3 and 5 in degenerated areas
were conﬁrmed by immunohistochemistry and protein quantiﬁcation
by BioPlex. These results indicated that the reduced response to IGFs
could account for the decline in cartilage matrix gene expression in
degenerated areas.
Next, cartilage explants were prepared from degenerated and preserved
areas, respectively, and treated with speciﬁc inhibitors for Akt signaling,
the dominant signal pathway activated by IGFs. This treatment reduced
the expression of type II collagen and aggrecan only in the explants
from preserved areas, but such a reduction was not observed in those
from degenerated areas, suggesting that Akt signaling had been already
attenuated in vivo in the degenerated areas.
In a variety of cells, expression of IGF1R and IRS1 is regulated by Sp1.
Thus, we investigated Sp1 expression within OA cartilage, and found that
its expression was obviously reduced in degenerated areas. We also found
that the expression levels of IGF1R and IRS1 were signiﬁcantly correlated
with that of Sp1 within human OA cartilage. Thus, in the degenerated
areas of OA cartilage, the expression of IGF1R and IRS1was considered
to be attenuated by the reduction in Sp1 expression. To conﬁrm this,
the expression of Sp1 in primary cultured human chondrocytes was
suppressed by RNAi or elevated by adenoviral transduction, which
indeed caused the increase or reduction of IGF1R and IRS1 expression,
respectively.
Conclusions: The result of this study has shown that the response of
chondrocytes to IGFs might be reduced in the degenerated areas of OA
cartilage. Since OA synovial ﬂuid contains substantial amounts of IGF-1,
reduced response to IGFs may well account for the decline in cartilage
matrix expression in degenerated areas within OA cartilage.
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Purpose: Age is the most prominent predisposition for development
of osteoarthritis (OA), a slowly progressive joint disease characterized
by gradual loss of articular cartilage. Age-related changes of articular
cartilage are likely to play a role. Advanced glycation endproducts (AGEs)
accumulate in the cartilage matrix with increasing age and adversely
affect the biomechanical properties of the cartilage matrix and inﬂuences
chondrocyte activity. These effects render the tissue more prone to
damage and may potentially lead to the development of OA. In clinical
studies AGEing of cartilage and its relation to actual cartilage damage
can only be measured by surrogate markers (e.g. serum, skin or urine
AGE levels and imaging or biochemical markers of cartilage damage).
Relations between AGEing and cartilage damage are found although
results are far from conclusive, maybe due to the limited relation
between cartilage AGE levels and AGE levels of surrogate compartments
or surrogate markers of cartilage damage. Thus far, a direct comparison
between cartilage AGE level and actual cartilage damage has not been
made. Therefore, the present study compares actual cartilage AGE levels
(in addition to urinary AGE levels) in OA directly with actual cartilage
damage by use of macroscopic, histological and biochemical analyses.
Methods: Cartilage from the femoral condyles of 69 knee OA patients
(average age: 68.8±9.0 years; 50/19 female/male ratio) undergoing
total knee replacement and urine samples were obtained and analysed
for pentosidine as marker of AGE. Cartilage damage was evaluated
by macroscopic, histological, and biochemical analyses (proteoglycan
turnover).
Results: Cartilage and urine pentosidine both increased with increasing
age (R =0.493 and R=0.535 resp. both with p =0.000) as previously found.
The higher the macroscopic cartilage damage the lower the cartilage
pentosidine amount (R = −0.286, p = 0.028). This inverse relation was also
found when related to the histological cartilage damage (R = −0.428,
p = 0.001). The biochemical analysis of cartilage damage corroborated
this as the different proteoglycan parameters also demonstrated an
inverse relation with cartilage pentosidine levels (PG content R =0.179,
p=NS; %PG synthesis R = 0.443, p = 0.000; % total PG released R=−0.392,
p = 0.002; and % newly formed GAG released R=−0.400, p = 0.002). Four
urine pentosidine similar results were found (R =0.057, ns; PG synthesis
rate: R = 0.279, p = 0.032; total PG release: R = −0.288, p = 0.027; newly
formed GAG release: R = −0.248, ns). In multiple regression analysis this
relationship seems to be independent of age. For cartilage histology, PG
synthesis, % total PG and newly formed GAG released as independent
variable and age as well as cartilage pentosidine as dependent variable in
most cases the explained variance was around 40% (R2 ≈0.4). The partial
regression coefﬁcient (B) was not signiﬁcant for age, but in all cases it
was for cartilage pentosidine.
Conclusions: There is an inverse relation between cartilage AGEs and
actual cartilage damage measured on different levels in end stage OA
using the cartilage tissue itself. This is contrasting the existing literature,
which show positive relations making use of indirect measurements. This
difference might be explained by the fact that in case of more severe
OA, the cartilage can contain lower amount of pentosidine due to newly
formed collagen not yet modiﬁed by the non-enzymatic glycation. What
the exact contribution of AGEs to OA progression is remains ambiguous.
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Background: Joint diseases such as osteoarthritis (OA) result in
destruction of articular cartilage. Transforming Growth factor beta is
considered as a protective factor in young cartilage while this function is
lost upon aging. In chondrocytes, TGF beta can signal via phosphorylation
of SMAD2/3 (via ALK5) or SMAD1/5/8 (via ALK1). In earlier studies
we have found that in young healthy human cartilage (age < 10 years)
only SMAD2/3 phosphorylation (SMAD2/3P) occurs and no SMAD1/5/8
phosphorylation (SMAD1/5/8P). Moreover, in human OA cartilage we
showed a signiﬁcant correlation between ALK1 and MMP13 expression.
Purpose: To study the expression of SMAD2/3P and SMAD1/5/8P in
chondrocyte populations in end-stage human OA cartilage and whether
addition of exogenous TGF beta modulates the expression of MMP13,
ALK5 and ALK1 in this cartilage.
Methods: Human OA articular cartilage was obtained during knee joint
replacement (n =20). Cartilage sections were stained for SMAD2/3P and
SMAD1/5/8P using speciﬁc antibodies. In addition, human OA cartilage
was incubated with 10ng/ml TGF beta for 24h. Part of the cartilage
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explants were pre-incubated with the ALK5 inhibitor SB-505124 (50mM)
for 6 hours. Expression of MMP13, ALK5 and ALK1 was analyzed by
quantitative PCR.
Results: Staining for both SMAD2/3P and SMAD1/5/8P was observed in
human OA cartilage. Strikingly, SMAD2/3P staining was mostly negative
in histological intact cartilage areas while cells in damaged areas, mainly
in chondrocyte clusters, were often strongly positive. Also staining for
SMAD1/5/8P was most intense in cells surrounding damaged regions and
chondrocyte clusters. Incubation of human OA cartilage with TGF beta
signiﬁcantly down regulated MMP13 expression. This effect was totally
abolished by the ALK5 inhibitor SB-505124. TGF beta also signiﬁcantly
elevated ALK5 expression, and decreased ALK1 expression, and both
these effects were completely blocked by pre-incubation with SB-
505124.
Conclusion: Stimulation of human end-stage OA cartilage with high TGF
beta concentrations down regulates MMP13 expression and modulates
TGF beta type I receptors, increasing the ALK5/ALK1 ratio. These effects
all run via SMAD2/3 (ALK5). We propose, based on these results and
earlier ﬁndings, that during aging TGF beta loses its protective role
by a loss of SMAD2/3 signaling in articular chondrocytes. This loss
plays a role in the initiation of cartilage degradation. In end-stage
OA cartilage the majority of cells does not display either SMAD2/3P
or SMAD1/5/8P. However, neighboring severely damaged cartilage a
population of chondrocytes is present, most probably involved in
(unsuccessful) repair, that expresses SMAD2/3P and SMAD1/5/8P.
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MOLECULAR DETECTION OF A PRECURSOR STAGE OF OSTEOARTHRITIS
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Purpose: Developmental dysplasia of hip (DDH) is recognized as a
potential risk factor for hip pain in young adults and a risk factor
for development of hip osteoarthritis (OA). Recently, femoroacetabular
impingement (FAI), with other dysmorphic and orientation abnormalities
of the hip joint, has been reported. Both conditions were presumed to be
in an early stage of degeneration based on their long term history and
radiographic evaluations, however, there are no reports of a biological
basis for early OA or discrimination of DDH and FAI. Therefore, the
purpose of this study was to determine the metabolic proﬁle of the
cartilage at the time of hip surgery to reshape the hip.
Methods: Fifty nine cartilage samples were obtained from patients
who had FAI (n = 26), DDH (n=13), and structural instability with
impingement (combined) (n = 20), at the time of their joint preservation
surgery, either surgical dislocation or/and periacetabular osteotomy.
Cartilage samples from 2 children were used as normal control, and
7 OA samples were used as disease controls. All cartilage samples were
harvested from their femoral neck junctions, and RNAs were extracted.
These cartilage samples were evaluated by real-time PCR assay of
gene expression of cytokines and chemokines, matrix molecules, and
degradative enzymes. The macroscopic cartilage damage was classiﬁed
by Beck’s criteria (normal, malacia, cleavage, and defect).
Results: RNA from both diseases presented high levels of speciﬁc
inﬂammatory cytokines (IL-1b and IL-8), chemokines (CXCL2, CXCL3,
CXCL6, CCL3 and CCL3L1), and degenerative mediators (MMP-13 and
ADAMTS-4), and this expression was higher in FAI than DDH or
combined. In addition, expression of Type II collagen (Col2A1) and
Aggrecan were higher in FAI compared to DDH and combined samples
(Figure 1).
Stratiﬁcation by age (<20 y.o., ≥20 y.o.) showed that older DDH and
combined samples expressed higher levels of some chemokines (CCL3L1
in DDH, CXCL1 and CXCL2 in combined) and catabolic enzymes (MMP-
13 in DDH, ADAMTS-4 in combined). In addition, the Col2A1 level was
lower in older samples (Figure 2).
Comparison between Beck’s classiﬁcation showed a higher expression of
a speciﬁc cytokine (IL-8), chemokines (CXCL1, CXCL3, CXCL6, and CCL3L1),
and ADAMTS-4 in samples with cartilage cleavage. Col2A1 expression
was gradually increased with advancing cartilage damage, while less
expression in OA samples.
Conclusions: The cartilage condition in both diseases is considered pre-
OA, based on the lack of radiographic OA. The cartilage of FAI has a high
level of metabolic activity with more arthritic character (high catabolic
factors) but also a regenerative response (high Col2A1 and Aggrecan).
In both DDH and combined patients, the overall level of metabolic
activity was lower than FAI, however the expression of degenerative
enzymes was age-dependent indicating cartilage degradation especially
in older patients. Therefore, both age and OA-related symptoms need
to be taken into account when considering surgical intervention. We
hypothesize that joint preservation surgery would decrease stress on
the articular cartilage and lower metabolic activity. In conclusion, we
have demonstrated that hip cartilage from young patients with FAI and
DDH has a unique biological character, which may lead to identiﬁcation
of speciﬁc biomarkers for detection of early degenerative changes and
outcomes following treatment.
Fig. 1. Expression levels of cytokines, matrix molecules, and chemokines
in FAI, DDH and combined samples. RNA expression was normalized
to GAPDH mRNA and then compared with normal cartilage samples
(set at 1). *Signiﬁcant difference between normal control.
Fig. 2. Stratiﬁcation by age (<20 y.o., ≥20 y.o.) in each disease. RNA
expression was normalized to GAPDH mRNA and then compared with
normal cartilage samples (set at 1). *Signiﬁcant difference between each
age group.
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Purpose: Osteoarthritis is the most common chronic joint disorder in
the US, affecting nearly one-tenth of the population. It is characterized
by degeneration of the articular cartilage, limited intra-articular
inﬂammation and synovitis, changes in sub-chondral bone and pain.
Nothing in the current standard of care preserves cartilage or carries a
claim of disease modiﬁcation in osteoarthritis; standard treatments focus
on symptom relief using NSAIDs, injected steroids, and viscosupplements.
IL-1, produced by chondrocytes in OA cartilage, promotes increased
expression and activation of aggrecanases and matrix metalloproteinases
